Purchase this article with an account.
Eric Fourmaux, marcel dominguez, laurence rosier, laurent velasque; One year’s treatment with intravitreal Ranibizumab (lucentis®) and Verteporfin PDTRf Combination Therapy at Month 2 for Neovascular Age-related Macular Degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2012;53(14):6525.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine if combination therapy with a single reduced fluence verteporfin PDT at Month 2 after retinal thickness lowering, reduces retreatment rates with ranibizumab, compared with Lucentis® monotherapy while maintaining similar vision outcomes and an acceptable safety profile.
In this retrospective, observational study, 40 patients with newly diagnosed subfoveal choroidal neovascularization due to AMD were treated by intravitreal injections of Lucentis® for at least one year (ranibizumab 0.5 mg, 3 consecutive monthly injections followed by PRN injections) and a single verteporfin PDT administered at reduced fluence (300 mW/cm2, 25J/cm2) on the day of the 2nd ranibizumab injection
Interim results were obtained from 27 patients who completed the one year follow-up. The mean VA at baseline was 66.7 (SD+7.4).The mean VA gain was +9.0 letters ETDRS (SD+7.4) and 26% (7/27) ≥ 15 letters EDTRS. The mean IVT number was 4.15 (SD+1.46), 48% (13/27) did not receive any further IVT after the loading phase and 81% (22/27) received ≤2 IVT after the loading phase.
Despite the high VA level at baseline, it seems that this protocol using a single verteperfin PDTRF administred later during the second IVT instead of during the first IVT provides a high vision gain associated with a low injection rate. The full analysis on the entire data set will be presented.
This PDF is available to Subscribers Only